Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model
Background Aripiprazole lauroxil (AL) is a long-acting injectable medication approved for
the treatment of schizophrenia. Current AL regimens are 441 mg, 662 mg, and 882 mg …
the treatment of schizophrenia. Current AL regimens are 441 mg, 662 mg, and 882 mg …
Pharmacokinetics, safety, and tolerability of a 2-month dose interval regimen of the long-acting injectable antipsychotic aripiprazole lauroxil: results from a 44-week …
Background Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic approved for
treatment of schizophrenia in adults. Approved AL doses and dosing regimens include 441 …
treatment of schizophrenia in adults. Approved AL doses and dosing regimens include 441 …
Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil
ML Hard, AY Wehr, BM Sadler, RJ Mills… - European journal of …, 2018 - Springer
Abstract Background and Objectives Aripiprazole lauroxil (AL), a long-acting injectable
antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole …
antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole …
Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia
ML Hard, RJ Mills, BM Sadler, RZ Turncliff… - Journal of clinical …, 2017 - journals.lww.com
Background Aripiprazole lauroxil is an extended-release prodrug of aripiprazole for
intramuscular injection, approved for schizophrenia treatment. We developed a population …
intramuscular injection, approved for schizophrenia treatment. We developed a population …
Aripiprazole lauroxil: a review in schizophrenia
JE Frampton - Drugs, 2017 - Springer
Aripiprazole lauroxil long-acting injectable (LAI)[Aristada®] is an intramuscularly
administered, extended-release prodrug of aripiprazole, an established atypical …
administered, extended-release prodrug of aripiprazole, an established atypical …
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
HA Nasrallah, R Aquila, Y Du, AD Stanford… - CNS …, 2019 - cambridge.org
ObjectiveSafety and tolerability of long-term treatment with the long-acting antipsychotic
aripiprazole lauroxil (AL) were evaluated in patients with schizophrenia. MethodsThis was …
aripiprazole lauroxil (AL) were evaluated in patients with schizophrenia. MethodsThis was …
Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia
Background Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the
treatment of schizophrenia, requires 21 days of oral aripiprazole supplementation upon …
treatment of schizophrenia, requires 21 days of oral aripiprazole supplementation upon …
Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison
Abstract Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a novel long-acting
injectable (LAI) formulation of aripiprazole monohydrate for administration once every 2 …
injectable (LAI) formulation of aripiprazole monohydrate for administration once every 2 …
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia
DW Boulton, G Kollia, S Mallikaarjun… - Clinical …, 2008 - Springer
Background and objective: Patients with schizophrenia or bipolar disorder who are
experiencing acute behavioural emergencies often require intramuscular injection of …
experiencing acute behavioural emergencies often require intramuscular injection of …
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil
L Citrome - Expert review of clinical pharmacology, 2016 - Taylor & Francis
Aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) are two different long-acting
injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated …
injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated …
相关搜索
- pharmacokinetic profile aripiprazole lauroxil
- dose regimen aripiprazole lauroxil
- pharmacokinetic profile dose regimen
- injectable antipsychotic aripiprazole lauroxil
- patients with schizophrenia aripiprazole lauroxil
- pharmacokinetic profile injectable antipsychotic
- pharmacokinetic profile persons with schizophrenia
- pharmacokinetic evaluation aripiprazole lauroxil
- injectable formulations aripiprazole lauroxil
- persons with schizophrenia aripiprazole lauroxil